Your browser doesn't support javascript.
loading
Relaxin reduces endothelium-derived vasoconstriction in hypertension: Revealing new therapeutic insights.
Leo, Chen Huei; Ng, Hooi Hooi; Marshall, Sarah A; Jelinic, Maria; Rupasinghe, Thusitha; Qin, Chengxue; Roessner, Ute; Ritchie, Rebecca H; Tare, Marianne; Parry, Laura J.
Afiliación
  • Leo CH; School of Biosciences, The University of Melbourne, Parkville, VIC, Australia.
  • Ng HH; School of Biosciences, The University of Melbourne, Parkville, VIC, Australia.
  • Marshall SA; Heart Failure Pharmacology, Baker Heart & Diabetes Institute, Melbourne, VIC, Australia.
  • Jelinic M; School of Biosciences, The University of Melbourne, Parkville, VIC, Australia.
  • Rupasinghe T; School of Biosciences, The University of Melbourne, Parkville, VIC, Australia.
  • Qin C; Metabolomics Australia, School of Biosciences, The University of Melbourne, Parkville, VIC, Australia.
  • Roessner U; Heart Failure Pharmacology, Baker Heart & Diabetes Institute, Melbourne, VIC, Australia.
  • Ritchie RH; Department of Pharmacology & Therapeutics, The University of Melbourne, Parkville, VIC, Australia.
  • Tare M; School of Biosciences, The University of Melbourne, Parkville, VIC, Australia.
  • Parry LJ; Metabolomics Australia, School of Biosciences, The University of Melbourne, Parkville, VIC, Australia.
Br J Pharmacol ; 177(1): 217-233, 2020 01.
Article en En | MEDLINE | ID: mdl-31479151
ABSTRACT
BACKGROUND AND

PURPOSE:

Endothelium-derived vasoconstriction is a hallmark of vascular dysfunction in hypertension. In some cases, an overproduction of endothelium-derived prostacyclin (PGI2 ) can cause contraction rather than relaxation. Relaxin is well known for its vasoprotective actions, but the possibility that this peptide could also reverse endothelium-derived vasoconstriction has never been investigated. We tested the hypothesis that short-term relaxin treatment mitigates endothelium-derived vasoconstriction in spontaneously hypertensive rats (SHR). EXPERIMENTAL

APPROACH:

Male Wistar Kyoto rats (WKY) and SHR were subcutaneously infused with either vehicle (20 mmol·L-1 sodium acetate) or relaxin (13.3 µg·kg-1 ·hr-1 ) using osmotic minipumps for 3 days. Vascular reactivity to the endothelium-dependent agonist ACh was assessed in vitro by wire myography. Quantitative PCR and LC-MS were used to identify changes in gene expression of prostanoid pathways and PG production, respectively. KEY

RESULTS:

Relaxin treatment ameliorated hypertension-induced endothelial dysfunction by increasing NO-dependent relaxation and reducing endothelium-dependent contraction. Notably, short-term relaxin treatment up-regulated mesenteric PGI2 receptor (IP) expression, permitting PGI2 -IP-mediated vasorelaxation. In the aorta, reversal of contraction was accompanied by suppression of the hypertension-induced increase in prostanoid-producing enzymes and reduction in PGI2 -evoked contractions. CONCLUSIONS AND IMPLICATIONS Relaxin has region-dependent vasoprotective actions in hypertension. Specifically, relaxin has distinct effects on endothelium-derived contracting factors and their associated vasoconstrictor pathways in mesenteric arteries and the aorta. Taken together, these observations reveal the potential of relaxin as a new therapeutic agent for vascular disorders that are associated with endothelium-derived vasoconstriction including hypertension.
Asunto(s)

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Relaxina / Vasoconstricción / Endotelio Vascular / Hipertensión Tipo de estudio: Prognostic_studies Límite: Animals Idioma: En Revista: Br J Pharmacol Año: 2020 Tipo del documento: Article País de afiliación: Australia

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Relaxina / Vasoconstricción / Endotelio Vascular / Hipertensión Tipo de estudio: Prognostic_studies Límite: Animals Idioma: En Revista: Br J Pharmacol Año: 2020 Tipo del documento: Article País de afiliación: Australia